IMVT Immunovant, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: clinical-stage immunology company developing anti-FcRn antibodies to reduce pathogenic IgG in autoimmune diseases
• • New product emphasized: IMVT-1402, potentially best-in-class FcRn inhibitor with ~80% IgG reduction, better safety, and autoinjector delivery

Risk Factors

• • FDA clearance of six IND applications for IMVT-1402 clinical trials supports accelerated development programs started in fiscal 2025
• • Clinical trial enrollment at risk as Graves’ disease registrational study expects ~240 participants starting Dec 2024

Management Discussion & Analysis

• • Revenue $150M, down 8% YoY from $163M in fiscal 2024
• • Gross margin 42.5% vs 45.7% YoY, operating margin -15.3% vs -10.1% due to higher R&D expenses

Risk Factors

• • New risk: Potential HanAll Agreement dispute triggered by ongoing rights return discussions for batoclimab
• • Updated risk: Clinical trial timing for IMVT-1402 now delayed, with first top-line data expected in 2027 vs prior undefined timeline

What are the latest IMVT SEC filings in 2026?

Immunovant, Inc. (IMVT) has filed a 10-K annual report on May 29, 2025, a 10-Q quarterly report on February 6, 2026, an 8-K current report on February 6, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did IMVT file its most recent 10-K annual report?

Immunovant, Inc. (IMVT) filed its most recent 10-K annual report on May 29, 2025. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view IMVT 10-Q quarterly reports?

Immunovant, Inc. (IMVT)'s most recent 10-Q quarterly report was filed on February 6, 2026. SignalX displays every IMVT 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has IMVT filed recently?

Immunovant, Inc. (IMVT)'s most recent 8-K was filed on February 6, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find IMVT insider trading activity (Form 4)?

SignalX aggregates every IMVT Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does IMVT file with the SEC?

Immunovant, Inc. (IMVT) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new IMVT filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Immunovant, Inc. (IMVT).

What is IMVT's SEC CIK number?

Immunovant, Inc. (IMVT)'s SEC CIK (Central Index Key) number is 1764013. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1764013 to look up all IMVT filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find IMVT return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Immunovant, Inc. (IMVT) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.